Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
* `2 s: e) \4 M6 n' K7 p, ^* u
) ^+ s! v) T8 x) Z# t- C% x: V2 h
Sub-category:4 a1 h1 }1 f+ g9 z, A/ F/ D
Molecular Targets 4 j# _, W9 H$ ~: A4 s! y! Y
/ g3 t7 N" |" q. v! \. `9 h/ Y9 a
Category:
4 Y. r4 m/ t+ X& NTumor Biology ( h: n* L2 n/ S0 a# N* w8 W
1 _, w T4 x( k' X) `
, B3 }7 b2 N! W; T, E" {" q5 j
Meeting:. h% p- K1 M7 Y, A. P
2011 ASCO Annual Meeting
! O6 g- x& I% v( f0 X
0 g$ d# [2 N9 i$ L( k; \" ~! Y1 c6 [3 v" }9 a4 l
Session Type and Session Title:
- W' R1 u( U. x* L! _/ C MPoster Discussion Session, Tumor Biology
6 ?9 i; N, q! B4 ]; D, C; P( N# c/ h7 B! v
" s0 M7 [0 u3 B) `* WAbstract No:# U) ]* s$ T7 m% a+ h2 y* F- e
10517
( p* x: m9 d3 }6 A( E- S- x
6 e# ^( q0 ^2 D6 O+ p1 ^4 ^- K
; v- B! g- X: `# k8 kCitation:& X' I" I' m2 I8 Z
J Clin Oncol 29: 2011 (suppl; abstr 10517)
5 A% U0 h% O) E8 r
6 `0 K. K V6 U1 M
+ R* H1 @& z" W- R s9 Q0 iAuthor(s):
) s/ i# u* n% a8 m. n$ ~J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 6 @6 F- F+ W$ e3 Q
% c! Q! n( S0 ^% H" T' R9 V& w) v) a8 X9 h$ [! V, O- C
8 ]! n7 z; a8 [* Z% A
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.# }; ^8 M) d+ Z! ]
) e7 S3 P1 J# V& q' W/ o- w; GAbstract Disclosures
j2 k/ \- _9 M4 G) X/ Z1 {. u; n: E0 v" Z2 }8 B
Abstract:4 m- z+ Y: e: s7 W; b3 b# I
8 A' i2 L/ y k/ p
/ O, F9 u% C, L' ^& Q- u' wBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
1 ?) ?7 q' h+ A2 C
4 t8 O+ i9 w. V! k4 H" J
2 w ]. l2 |' M5 w: L |
急急急 肺癌晚期求助
爷爷现在的情况
1.全身都疼，吃了止痛药和贴了膏药虽然疼痛有所缓解，但还是疼
2.最近
MET抑制剂引发水肿的应对技巧
作者：雨过天晴
在非小细胞肺癌（NSCLC）的治疗中，靶向药物的出现为患者带来了新的希
同步放化疗结束3年，化免联合后单免
恳请各位帮忙指导！
2021年7月开始根治性调强放疗，总计33次。近4年治疗方案较简单，
肺鳞癌L858R 达克替尼近三年耐药
71岁，女，无吸烟史
18年10月肺鳞癌，3X 4cm，左肺上叶切除，无转移，未化疗
22年1月
奥西替尼耐药后续治疗，出现腹水
治疗经过：
2010确诊腺癌
治疗方案：右肺上叶切除，10年民诺宾2次，顺铂+盖诺2次。
5 U( @, p! j" [1 h; @
显身卡
